• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis announces commercial team expansion
Share
News

ProAxsis announces commercial team expansion

June 21, 2021
-
Posted by David Ribeiro

As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce two new appointments within its commercial team. 

Nina Morrison joins the company as Business Development Manager.  Nina brings a wealth of field-based commercial experience to ProAxsis, having previously held roles at major pharmaceutical companies including Pfizer and Bayer Healthcare, with a focus on point-of-care testing and medical devices.

In addition, Jessica Robinson takes on the role of Sales & Marketing coordinator, based at the ProAxsis offices at Catalyst in Belfast.  Jessica has just completed a BSc in International Business with Spanish at Queen’s University Belfast.

Dr David Ribeiro, CEO of ProAxsis, said: “In line with our stated strategy to expand our commercial operation, we believe that Nina and Jessica provide significant additional skills to the ProAxsis team and will enable enhanced promotion of our protease biomarker assays as well as our newly in-licensed assays from AstraZeneca and the University of Geneva.  We’re delighted that they’ve both agreed to join the company.”

Nina Morrison, newly appointed Business Development Manager at ProAxsis, added: “I’m thrilled to be joining ProAxsis at such an exciting period of expansion for the company.  With the recently announced in-licensing deals with both AstraZeneca and the University of Geneva, together with our existing assets of lab-based protease assays and NEATstik®, I can’t wait to get started and look forward to meeting existing and new customers at the earliest opportunity.”

Due to the growing nature of the company, we continue to look for high-quality candidates to join our team.  Any new opportunities will be posted on our website – www.proaxsis.com

About ProAxsis

ProAxsis Limited is a commercial diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.

June 21, 2021

Related News

Other posts that you should not miss.
News, ProteaseTag®

ProAxsis abstracts at 2017 European Respiratory Society Conference

September 6, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes …

Read More
September 6, 2017
Posted by Webmaster
NEATstik®, News

ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

September 4, 2017
-
Posted by Webmaster

ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care …

Read More
September 4, 2017
Posted by Webmaster
News

ProAxsis presents exciting new data at the ERS International Congress 2021

September 3, 2021
-
Posted by Jessica Robinson

ProAxsis are delighted to announce that the company will be presenting results from several recent projects at …

Read More
September 3, 2021
Posted by Jessica Robinson
← PREVIOUS POST
Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests
NEXT POST →
ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis announces commercial team expansion - ProAxsis